Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Mol Cancer Res. 2017 Sep 14;15(12):1741–1751. doi: 10.1158/1541-7786.MCR-17-0010

Figure 5. PRELID1 APA, but not transcript abundance, influences breast cancer outcomes in a subtype-dependent manner.

Figure 5

Overall survival split by median PRELID1 Exon 4/Exon 5 ratio (A–B) or median PRELID1 Exon 4 expression (C–D) in ER− (A,C) and ER+ (B,D) patients. *p<0.05, **p<0.01, ***p<0.001